Vision of the future: Capecitabine

Oncologist

Volumn 6, Issue SUPPL. 4, 2001, Pages 35-39

  Twelves, Chris ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

5 FU; Breast cancer; Capecitabine; Ovarian cancer; Pancreatic cancer; Renal cell cancer; Thymidine phosphorylase

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; KIDNEY CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 0034792770     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_4-35     Document Type: Conference Paper

References (15)

1. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
2. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
3. Capecitabine: Preclinical pharmacology studies
4. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
5. Results of a large phase III trial of Xeloda/Taxotere® combination therapy vs Taxotere® monotherapy in metastatic breast cancer (MBC) patients
6. Schedule-dependency of antitumor activity in combination therapy with capecitabine (Xeloda®) and docetaxel in breast cancer models
7. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
8. A phase 2 trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer
9. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer
10. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial
11. A phase II trial of capecitabine (Xeloda) in relapsed ovarian cancer
12. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
13. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy
14. Capecitabine in the treatment of metastatic renal cell carcinoma